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Several members of the genus Burkholderia are prominent pathogens. Infections
caused by these bacteria are difficult to treat because of significant antibiotic
resistance. Virtually all Burkholderia species are also resistant to polymyxin, prohibiting
use of drugs like colistin that are available for treatment of infections caused
by most other drug resistant Gram-negative bacteria. Despite clinical significance
and antibiotic resistance of Burkholderia species, characterization of efflux pumps
lags behind other non-enteric Gram-negative pathogens such as Acinetobacter
baumannii and Pseudomonas aeruginosa. Although efflux pumps have been described
in several Burkholderia species, they have been best studied in Burkholderia
cenocepacia and B. pseudomallei. As in other non-enteric Gram-negatives, efflux
pumps of the resistance nodulation cell division (RND) family are the clinically
most significant efflux systems in these two species. Several efflux pumps were
described in B. cenocepacia, which when expressed confer resistance to clinically
significant antibiotics, including aminoglycosides, chloramphenicol, fluoroquinolones,
and tetracyclines. Three RND pumps have been characterized in B. pseudomallei, two
of which confer either intrinsic or acquired resistance to aminoglycosides, macrolides,
chloramphenicol, fluoroquinolones, tetracyclines, trimethoprim, and in some instances
trimethoprim+sulfamethoxazole. Several strains of the host-adapted B. mallei, a clone
of B. pseudomallei, lack AmrAB-OprA, and are therefore aminoglycoside and macrolide
susceptible. B. thailandensis is closely related to B. pseudomallei, but non-pathogenic
to humans. Its pump repertoire and ensuing drug resistance profile parallels that
of B. pseudomallei. An efflux pump in B. vietnamiensis plays a significant role in
acquired aminoglycoside resistance. Summarily, efflux pumps are significant players in
Burkholderia drug resistance.
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The Genus Burkholderia
The genus Burkholderia comprises metabolically diverse and adaptable Gram-negative bacteria
that are able to thrive in diﬀerent, often adversarial, environments. Their metabolic versatility and
adaptability is in part due to the coding capacity provided by large (7–9 Mb) genomes consisting of
several chromosomes and in some species, e.g., Burkholderia cenocepacia, plasmids (Holden et al.,
2004, 2009; Agnoli et al., 2012). Many members of the genus are clinically signiﬁcant pathogens
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with renowned virulence potential (Tegos et al., 2012) and drug
resistance (Burns, 2007). In contrast tomost other Gram-negative
pathogens, Burkholderia species are intrinsically polymyxin resis-
tant and therefore colistin cannot be used as drug of last resort
(Loutet and Valvano, 2011). Despite clinical signiﬁcance and
recognized antibiotic resistance of Burkholderia species, charac-
terization of eﬄux pumps lags signiﬁcantly behind other non-
enteric Gram-negative pathogens such as Acinetobacter bauman-
nii and Pseudomonas aeruginosa (Nikaido and Pages, 2012).
Many Burkholderia eﬄux systems have homologs in other Gram-
negatives, including A. baumannii and P. aeruginosa, and it is
now generally believed that the multidrug resistance exhibited
by these opportunistic pathogens is largely attributable to the
existence of similar eﬄux pumps in these organisms (Poole,
2001; McGowan, 2006). As with other Gram-negative bacteria,
the relative roles that individual eﬄux pumps play in intrinsic
or acquired antibiotic resistance in the respective Burkholderia
species are in many instances diﬃcult to discern for various rea-
sons: (1) a subset of the pumps found in any organism usually
exhibits a considerable degree of substrate promiscuity, i.e., they
recognize and extrude chemically and structurally diverse com-
pounds, which leads to similar multidrug resistance proﬁles; (2)
many of the eﬄux systems are not expressed at signiﬁcant lev-
els in wild-type strains under laboratory conditions and there
exists a signiﬁcant knowledge gap regarding the environmental
conditions under which eﬄux genes are expressed; and (3) well
characterized clinical or laboratory isolates expressing or lack-
ing the respective eﬄux pumps often do not exist or are diﬃcult
to obtain (Mima and Schweizer, 2010; Coenye et al., 2011; Biot
et al., 2013; Buroni et al., 2014). In this review we will summa-
rize the current state of knowledge of eﬄux pumps and their
roles in antibiotic resistance in the genus Burkholderia, which
have been characterized to various degrees in a few representative
organisms.
Burkholderia cepacia Complex
The Burkholderia cepacia complex (BCC) currently comprises 17
closely related species (Mahenthiralingam et al., 2005; Vanlaere
et al., 2009; Vandamme and Dawyndt, 2011). Some BCC mem-
bers exhibit beneﬁcial aspects such as use in biocontrol, a practice
that has since been abandoned because of the risk of infec-
tion of compromised individuals (Kang et al., 1998). Many are
opportunistic pathogens, being particularly problematic for cys-
tic ﬁbrosis patients and immune compromised individuals. B.
cenocepacia and B. multivorans account for 85% of all BCC infec-
tions (Drevinek and Mahenthiralingam, 2010). BCC infections
are diﬃcult to treat because of intrinsic antibiotic resistance and
persistence in the presence of antimicrobials (Golini et al., 2004;
Peeters et al., 2009; Rajendran et al., 2010; Jassem et al., 2011). B.
vietnamiensis belongs to the BCC group and sporadically infects
cystic ﬁbrosis patients (Jassem et al., 2011).
Burkholderia pseudomallei
Burkholderia pseudomallei is a saprophyte and opportunistic
pathogen endemic to tropical and subtropical regions of the
world, and recent studies suggest that is more widespread than
previously thought (Wiersinga et al., 2006, 2012, 2015; Currie
et al., 2010). Since the U.S. anthrax attacks in 2001 the bacterium
has received increasing attention because of its biothreat potential
(Cheng et al., 2005), a history dating back to its use with mali-
cious intent in a Sherlock Holmes short story (Vora, 2002). In
the U.S. it is a strictly regulated Tier 1 select agent, which must
be handled in approved biosafety level 3 (BSL-3) laboratories.
The bacterium is the etiologic agent of melioidosis, a diﬃcult-
to-treat multifacteted disease (Wiersinga et al., 2006, 2012). The
disease aﬀects at-risk patients, including those suﬀering from cys-
tic ﬁbrosis (Schulin and Steinmetz, 2001; Holland et al., 2002),
non-cystic ﬁbrosis bronchiectasis (Price et al., 2013), and diabetes
(Simpson et al., 2003). B. pseudomallei infections are recalci-
trant to antibiotic therapy because of the bacterium’s intrinsic
resistance due to expression of resistance determinants such as
β-lactamase and eﬄux pumps, as well as contributing factors such
as both intracellular and bioﬁlm lifestyles (Schweizer, 2012b).
Burkholderia mallei
Burkholderia mallei is an obligate zoonotic pathogen and the eti-
ologic agent of glanders, which has been used as a bioweapon
(Cheng et al., 2005; Whitlock et al., 2007). This bacterium likely
diverged from B. pseudomallei upon introduction into an ani-
mal host approximately 3.5 million years ago (Losada et al., 2010;
Song et al., 2010). The ensuing in-host evolution through massive
expansion of insertion (IS) elements, IS-mediated gene deletion,
and genome rearrangement, and prophage elimination is likely
also responsible for the generally increased antibiotic susceptibil-
ity of B. mallei when compared to B. pseudomallei, presumably
due to inactivation of resistance determinants (Nierman et al.,
2004).
Burkholderia thailandensis
Burkholderia thailandensis is closely related to B. pseudomallei
(Brett et al., 1998). Although B. thailandensis has sporadically
been shown to cause human disease (Glass et al., 2006), it is gen-
erally considered non-pathogenic and has often been used as a
surrogate for antimicrobial compound and vaccine eﬃcacy stud-
ies because the bacterium can be handled at BSL-2. Some strains
are more closely related to B. pseudomallei than others. For
instance, unlike the widely used B. thailandensis prototype strain
E264 (Brett et al., 1998), strain E555 expresses the same capsular
polysaccharide as B. pseudomallei (Sim et al., 2010). Since cap-
sular polysaccharide is a potent immunogen this similarity was
exploited in a vaccine study, which showed that immunization
with live cells of this avirulent strain protects mice from challenge
with a virulent B. pseudomallei strain (Scott et al., 2013).
Burkholderia cenocepacia
Efflux Pumps and Drug Resistance
Early reports provided mostly indirect evidence that B. ceno-
cepacia eﬄux pumps play a role in drug eﬄux. The synergy
between reduced outer membrane permeability and eﬄux was
cited as a common theme of the increased resistance that non-
fermenting Gram-negative bacteria like A. baumannii, P. aerug-
inosa, and B. (ceno)cepacia display (Hancock, 1998). An analysis
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of the DsbA–DsbB disulﬁde bond formation system revealed that
dsbA and dsbB mutation resulted increased susceptibilities to a
variety of antibiotics (Hayashi et al., 2000). This led to the con-
clusion that the DsbA–DsbB system might be involved in the
formation of a multidrug resistance system. Another early report
described an outer membrane lipoprotein involved in multiple
antibiotic (chloramphenicol, trimethoprim, and ciproﬂoxacin)
resistance (Burns et al., 1996). This protein, OpcM, is the outer
membrane channel of an eﬄux pump of the resistance nodu-
lation cell division (RND) family that was subsequently named
CeoAB-OpcM, which was shown to be inducible by salicylate
and chloramphenicol (Nair et al., 2004). Eﬄux was also shown
early on to play a role in ﬂuoroquinolone resistance (Zhang et al.,
2001).
Genome analysis and homology searches led to identiﬁcation
of an additional 14 open reading frames encoding putative com-
ponents RND family eﬄux pumps (Guglierame et al., 2006). A
summary of pertinent features of at least partially characterized
B. cenocepacia RND eﬄux pumps and their relationships to RND
systems in other Burkholderia species is presented in Table 1.
Expression of one of these, orf2, in Escherichia coli conferred
resistance to several antibiotics (Guglierame et al., 2006). The
roles of several RND transporters – RND-1, RND-3, and RND-
4 – in intrinsic B. cenocepacia drug resistance was subsequently
assessed by mutational analyses, which showed that RND-3 and
RND-4, but not RND-1, contribute to B. cenocepacia’s intrinsic
resistance to antibiotics and other inhibitory compounds (Buroni
et al., 2009). A subsequent study comparing RND-4 and RND-
9 single and double mutants conﬁrmed the role that RND-4
plays in B. cenocepacia’s antibiotic resistance and also showed
that RND-9 contributed only marginally to resistance (Bazzini
et al., 2011b). Completion of the strain J2315 genome sequence
showed that it encodes 16 RND eﬄux systems, which provides
evidence for the biological relevance of these transporters in this
bacterium and also enables global analyses of RND pump expres-
sion (Holden et al., 2009; Perrin et al., 2010; Bazzini et al., 2011a;
Buroni et al., 2014). For example, deletion of the 16 putative
RND operons from B. cenocepacia strain J2315 showed that these
pumps play diﬀerential roles in the drug resistance of sessile
(bioﬁlm) and planktonic cells. These studies revealed that: (1)
TABLE 1 | Partially characterized resistance nodulation cell division (RND) efflux pumps in Burkholderia species.
Species Efflux pump Gene names Gene annotation Major substrates Reference
Burkholderia
cenocepacia
RND-1 NA BCAS0591–BCAS0593 Non-detectable Buroni et al. (2009)
RND-3 NA1 BCAL1674–BCAL1676 Nalidixic acid, ciprofloxacin,
tobramycin, chlorhexidine3
Buroni et al. (2009, 2014),
Coenye et al. (2011)
RND-4 NA2 BCAL2820–BCAL2822 Aztreonam, chloramphenicol,
fluoroquinolones, tobramycin
Bazzini et al. (2011b)
RND-8 NA BCAM0925–BCAM0927 Tobramycin3 Buroni et al. (2014)
RND-9 NA BCAM1945–BCAM1947 Tobramycin3 , chlorhexidine3 Coenye et al. (2011), Buroni
et al. (2014)
RND-10 ceoAB-opcM4 BCAM2551–BCAM2549 Chloramphenicol, fluoroquinolones,
trimethoprim
Nair et al. (2004)
B. pseudomallei
AmrAB-OprA amrAB-oprA BPSL1804–BPSL1802 Aminoglycosides, macrolides,
cethromycin
Moore et al. (1999), Mima et al.
(2011)
BpeAB-OprB bpeAB-oprB BPSL0814–BPSL0816 Chloramphenicol, fluoroquinolones,
macrolides, tetracyclines5
Chan et al. (2004), Mima and
Schweizer (2010)
BpeEF-OprC bpeEF-oprC BPSS0292–BPSS0294 Chloramphenicol, fluoroquinolones,
tetracyclines, trimethoprim6
Kumar et al. (2006), Schweizer
(2012a,b)
B. thailandensis
AmrAB-OprA amrAB-oprA BTH_I2445–BTH_I2443 Aminoglycosides, macrolides,
tetracyclines
Biot et al. (2013)
BpeAB-OprB bpeAB-oprB BTH_I0680–BTH_I0682 Tetracyclines Biot et al. (2013)
BpeEF-OprC bpeEF-oprC BTH_II2106–BTH_II2104 Chloramphenicol, fluoroquinolones,
tetracyclines,
trimethoprim/sulfamethoxazole
Biot et al. (2011, 2013)
B. vietnamiensis
AmrAB-OprM amrAB-oprM Bcep1808_1574–
Bcep1808_1576
Aminoglycosides Jassem et al. (2014)
NA, not applicable
1Corresponds to B. pseudomallei amrAB-oprA
2Corresponds to B. pseudomallei bpeAB-oprB
3Sessile (biofilm grown) cells only
4Corresponds to B. pseudomallei bpeEF-oprC
5Low-level resistance in de-repressed (bpeR) strains
6High-level resistance in regulatory mutants, e.g., bpeT carboxy-terminal mutations
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RND-3 and RND-4 play important roles in resistance to various
antibiotics, including ciproﬂoxacin and tobramycin, in plank-
tonic populations; (2) RND-3, RND-8, and RND-9 protect from
the antimicrobial eﬀects of tobramycin in bioﬁlm cells; and (3)
RND-8 and RND-9 do not play a role in ciproﬂoxacin resistance
(Buroni et al., 2014). An emerging theme from these studies is
that RND-3 seems to play amajor role in B. cenocepacia’s intrinsic
drug resistance. It was suggested that mutations in the RND-
3 regulator-encoding gene may be responsible for this pump’s
prevalent overexpression and accompanying high-level antibiotic
resistance in clinical BCC isolates (Tseng et al., 2014).
Studies aimed at assessing chlorhexidine mechanisms in B.
cenocepacia J2315 conﬁrmed the diﬀerential roles that RND
pumps play in bioﬁlm versus planktonically grown cells. RND-
4 contributed to chlorhexidine resistance in planktonic cells,
whereas RND-3 and RND-9 played a role in chlorhexidine resis-
tance in sessile cells (Coenye et al., 2011). Mutational analyses
of 2-thiopyridine resistant mutants showed that RND-4 con-
fers resistance to an anti-tubercular 2-thiopyridine derivative
(Scoﬀone et al., 2014). The involvement of eﬄux pumps in tigecy-
cline resistance was inferred from the potentiating eﬀects of the
eﬄux pump inhibitor (EPI) MC-207,110 on tigecycline’s anti-B.
cenocepacia activity (Rajendran et al., 2010).
Eﬄux pumps belonging to other families may also contribute
to B. cenocepacia’s drug resistance. Experiments with an immun-
odominant antigen in cystic ﬁbrosis patients infected with B.
cenocepacia identiﬁed a drug eﬄux pump, BcrA, which is a mem-
ber of the major facilitator superfamily (MFS). It was shown to
confer tetracycline and nalidixic acid resistance when expressed
in E. coli (Wigﬁeld et al., 2002). Upregulation of an eﬄux pump
resulted in resistance to the phosphonic acid antibiotic fos-
ﬁdomycin (Messiaen et al., 2011). This pump is a homolog of Fsr,
a member of the MFS, which was previously shown to confer fos-
midomycin resistance on E. coli (Fujisaki et al., 1996; Nishino and
Yamaguchi, 2001).
Other Functions of B. cenocepacia RND
Efflux Pumps
As with other Gram-negative bacteria, the function of B. ceno-
cepacia eﬄux pumps extends beyond antibiotic resistance. In
B. cenocepacia, these systems are involved in modulation of
virulence-associated traits such as quorum sensing, bioﬁlm for-
mation, chemotaxis, and motility, as well as general physio-
logical functions (Buroni et al., 2009; Bazzini et al., 2011a,b).
A proteomic analysis of the eﬀects of RND-4 gene dele-
tion revealed about 70 diﬀerentially expressed proteins, most
of which were associated with cellular functions other than
drug resistance. This suggests that RND-4 plays a more gen-
eral role in B. cenocepacia’s biology (Gamberi et al., 2013).
Aside from the key role that eﬄux, especially RND-mediated
eﬄux, plays in adaptation to antibiotic exposure (Bazzini
et al., 2011b; Sass et al., 2011; Tseng et al., 2014), survival
of Burkholderia species in various niche environments and
accompanying conditions, e.g., the cystic ﬁbrosis airways (Mira
et al., 2011), marine habitats (Maravic et al., 2012), oxygen
levels (Hemsley et al., 2014), exposure to noxious chemicals
(Rushton et al., 2013), and other ecological niches (Liu et al.,
2015), involves to various degrees changes in eﬄux pump
expression.
Burkholderia pseudomallei
Efflux Pumps and Drug Resistance
Initially, the presence of genomic DNA sequences in B. pseu-
domallei that hybridize with the multidrug resistance eﬄux
gene oprM of P. aeruginosa was interpreted as evidence that
eﬄux-mediated multidrug eﬄux systems may also be present
in B. pseudomallei (Bianco et al., 1997). A recent survey of
documented B. pseudomallei antibiotic resistance mechanisms
indeed showed that eﬄux is the dominant mechanism aﬀect-
ing most classes of antibiotics (Schweizer, 2012b). Sequenced
B. pseudomallei genomes encode numerous eﬄux systems, but
as with other non-enteric bacteria only RND pumps have
to date been shown to confer resistance to clinically sig-
niﬁcantly antibiotics. The K96243 and other B. pseudomallei
genomes encode at least 10 RND systems, seven of which are
encoded by chromosome 1 and three by chromosome 2 (Holden
et al., 2004; Figure 1A). Although RND operon distribution
is conserved amongst diverse B. pseudomallei strains, locations
on the respective chromosomes may vary because of chro-
mosome rearrangements. Bioinformatic analyses indicate that
not all of the RND operons encode drug eﬄux pumps. For
instance, one system seems to encode components of a gen-
eral secretion (Sec) system. Although the presence of many
RND systems can be detected in clinical and environmental
isolates at the transcriptional (Kumar et al., 2008) and pro-
tein level (Schell et al., 2011), this expression is not neces-
sarily linked to increased drug resistance. Meaningful stud-
ies to address their function are complicated because isoge-
netic progenitor and/or comparator strains are generally not
available. Further hindering eﬄux pump characterization are
select agent guidelines, which restrict certain methods, such
as selection of spontaneous drug resistant mutants that may
display altered eﬄux expression proﬁles. These investigations
are now facilitated by the availability of several B. pseudo-
mallei strains, for instance Bp82 (Propst et al., 2010), which
are excluded from select agent rulings. To date three RND
drug eﬄux pumps – AmrAB-OprA, BpeAB-OprB, and BpeEF-
OprC – have been characterized in some detail (Figure 1B).
There is evidence that small molecule compounds such as MC-
207,110, phenothiazine antipsychotics, and antihistaminic drugs
like promazine can be used to potentiate antibiotic eﬃcacy,
primarily by inhibition of RND eﬄux pumps (Chan et al.,
2007b).
AmrAB-OprA
The AmrAB-OprA eﬄux pump was the ﬁrst eﬄux pump
described in B. pseudomallei (Moore et al., 1999). It is respon-
sible for this organism’s high-level intrinsic aminoglycoside
and macrolide resistance (Moore et al., 1999; Viktorov et al.,
2008). Rare (∼1 in 1,000) naturally occuring aminoglycoside
susceptible B. pseudomallei isolates have previously been iden-
tiﬁed (Trunck et al., 2009; Podin et al., 2014). They do not
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FIGURE 1 | Genomic location and operon organization of Burkholderia
pseudomallei resistance nodulation cell division (RND) efflux pumps.
(A) Chromosomal locations of RND efflux operons in strain K96243. Red
arrows indicate the approximate locations and transcriptional orientations of
RND operons on chromosomes 1 and 2. Operons encoding characterized
efflux pumps are labeled. Although RND operon distribution is conserved
amongst diverse B. pseudomallei strains, locations on the respective
chromosomes may vary because of chromosome rearrangements. The
origins of replication (ori) in the two strain K96243 chromosomes are marked.
Their respective locations on the chromosomes of other strains may vary
because of chromosome rearrangements. (B) Transcriptional organization of
characterized RND operons. The genes encoding the membrane fusion
proteins (amrA, bpeA, bpeE), RND transporter (amrB, bpeB, bpeF ) and outer
membrane protein channel (oprA, oprB, oprC) are color-coded. The
bpeE–bpeF–oprC genes are in the same operon as llpE, which is annotated
as a putative lipase/carboxyl esterase. LlpE is not required for BpeEF-OprC
efflux pump function. Orthologs of LlpE are present in all annotated operons
that encode bpeE–bpeF–oprC orthologs. The amrR and bpeR genes encode
repressors of amrAB-oprA and bpeAB-oprB, respectively. The bpeT gene
encodes a LysR-type transcriptional regulator of llpE-bpeE-bpeF-oprC.
express the AmrAB-OprA pump either due to regulatory muta-
tions (Trunck et al., 2009), point mutations aﬀecting the AmrB
RND transporter amino acid sequence (Podin et al., 2014),
or because the entire amrAB-oprM operon is missing due
to a genomic deletion (Trunck et al., 2009). Although the
AmrAB-OprA eﬄux pump is expressed in prototype strains,
exposure to antimicrobials can select for unknown mutations
that cause its over-expression resulting in increased resistance.
For instance, prototype strain 1026b is moderately suscepti-
ble [minimal inhibitory concentration (MIC) 4–8 μg/mL] to
the ketolide cethromycin and exposure to this compound read-
ily selects for highly resistant (MIC > 128 μg/mL) deriva-
tives due to AmrAB-OprA over-expression (Mima et al., 2011).
To date, AmrAB-OprA expression is the sole reported amino-
glycoside and macrolide resistance mechanism observed in
B. pseudomallei.
AmrAB is closely related to P. aeruginosa MexXY, which is
expressed in some aminoglycoside resistant mutants and together
with OprM constitutes a functional eﬀux pump (Mine et al., 1999;
Sobel et al., 2003; Morita et al., 2012). MexXY associates with the
mexAB-oprM encoded OprM outer channel protein because the
mexXY operons of most P. aeruginosa strains do not encode a
cognate outer mebrane channel protein. However, some strains,
e.g., P. aeruginosa PA7, encode a mexAB-oprA operon akin and
functionally equivalent to B. pseudomallei amrAB-oprA (Morita
et al., 2012).
BpeAB-OprB
The BpeAB-OprB eﬄux pump was ﬁrst described in strain
KHW from Singapore (Chan et al., 2004) and subsequently char-
acterized in Thai strain 1026b (Mima and Schweizer, 2010).
It is not signiﬁcantly expressed in wild-type strains. BpeAB-
OprB expression is regulated by BpeR and bpeR mutants exhibit
low-level chloramphenicol, ﬂuoroquinolone, tetracycline, and
macrolide resistance (Chan et al., 2004; Chan and Chua, 2005;
Mima and Schweizer, 2010). Although the original studies
with strain KHW indicated a role of BpeAB-OprB in amino-
glycoside resistance (Chan et al., 2004), these results could
not be conﬁrmed with strain 1026b (Mima and Schweizer,
2010). At present, the observed diﬀerences in BpeAB-OprB
substrate spectrum between strains KHW and 1026b are
not understood. Because of the low levels of resistance
bestowed by BpeAB-OprB and naturally occuring antibiotic
resistant BpeAB-OprB over-expressing mutants have yet to
be identiﬁed, the clinical signiﬁcance of this pump remains
unclear.
Although BpeAB-OprB is related to P. aeruginosa MexAB-
OprM (Poole et al., 1993; Li et al., 1995; Mima and Schweizer,
2010), the respective features are quite divergent. While P. aerug-
inosa MexAB-OprM is widely expressed and responsible for
this bacterium’s intrinsic resistance to numerous antibacterial
compounds (Poole et al., 1993; Li et al., 1995; Poole, 2001),
B. pseudomallei BpeAB-OprB is not widely expressed and does
seem to play only a minor role in this bacterium’s resistance to
antimicrobials.
BpeEF-OprC
BpeEF-OprC was ﬁrst identiﬁed as a chloramphenicol
and trimethoprim eﬄux pump by expression in an
eﬄux-compromised P. aeruginosa strain (Kumar et al.,
2006). This pump is not expressed in B. pseudomallei wild-
type strains, but only regulatory mutants. For instance,
it is constitutively expressed in naturally occuring bpeT
mutants (Hayden et al., 2012; Figure 2). When expressed,
BpeEF-OprC confers high-level resistance to chlorampheni-
col, ﬂuoroquinolones, tetracyclines, and trimethoprim. It is
responsible for widespread trimethoprim resistance in clin-
ical and environmental B. pseudomallei isolates (Podnecky
et al., 2013). Pump expression is inducible by some pump
substrates, which when present at sub MIC levels may lead
to cross-resistance with other pump substrates (Schweizer,
2012a).
BpeEF-OprC is related to P. aeruginosa MexEF-OprN
(Koehler et al., 1997), which shares properties such as substrate
proﬁles and selection of pump-expressing regulatory mutants by
chloramphenicol as previously demonstrated with both P. aerug-
inosa MexEF-OprN (Koehler et al., 1997) and B. thailandensis
BpeEF-OprC (Biot et al., 2011).
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FIGURE 2 | The transcriptional regulator BpeT and locations of
mutations causing multidrug resistance due to BpeEF-OprC
expression. The figure illustrates the cause of BpeEF-OprC expression
leading to a multidrug resistance phenotype due to bpeT mutations by
comparing a prototype strain, in this instance a primary melioidosis isolate
(strain 354b; Top), and a relapse isolate (strain 354e; Bottom). Strain 354b
(Top) expresses wild-type BpeT that exhibits the typical LysR-type regular
organization with an amino-terminal helix-turn-helix (HTH) DNA-binding
domain and a co-inducer binding site located within the carboxy-terminal half.
Point mutations located within the latter domain result in constitutive
BpeEF-OprC efflux pump expression. Strain 354e (Bottom) expresses
BpeEF-OprC constitutively due to deletion of the last 14 native bpeT codons
as a consequence of a 800 kb inversion affecting chromosome 2 (Hayden
et al., 2012).
Other Functions of B. pseudomallei Efflux
Pumps
Quorum sensing is an important determinant of virulence factor
regulation in bacteria. Numerous studies with P. aeruginosa indi-
cate the involvement of several RND pumps in quorum sensing
and thus several virulence traits by being involved in transport
of cell-to-cell signaling molecules and their inhibitors (Evans
et al., 1998; Pearson et al., 1999; Koehler et al., 2001; Aendekerk
et al., 2005; Hirakata et al., 2009; Tian et al., 2009). At least one
eﬄux pump regulator, MexT, modulates expression of virulence
factors, albeit independent of the function of the MexEF-OprN
eﬄux pump whose expression it regulates (Tian et al., 2009). A P.
aeruginosaMexAB-OprM deletion strain is also compromised in
its ability to invade Madin–Darby canine kidney (MDCK) cells
(Hirakata et al., 2009). Based on these ﬁndings with P. aerug-
inosa, several studies with B. pseudomallei explored the eﬀects
of eﬄux on quorum sensing and virulence. Studies with strain
KHW showed that the BpeAB-OprB eﬄux pump was required:
(1) for the secretion of the acyl homoserine lactones produced by
this strains quorum-sensing systems (Chan et al., 2007a); and (2)
secretion of several virulence-associated determinants, includ-
ing siderophore and bioﬁlm formation (Chan and Chua, 2005),
but these observations could not be conﬁrmed with strain 1026b
(Mima and Schweizer, 2010). Cell invasion of and cytotoxic-
ity toward human A549 lung epithelial and THP-1 macrophage
cell were signiﬁanctly reduced in a KHW BpeAB-deﬁcient strain
(Chan and Chua, 2005). Adherence to A549 cells and virulence in
the BALB/c mouse intranasal infection model were not aﬀected
in the AmrAB-OprA deﬁcient Bp340 mutant, a derivative of
strain 1026b (Campos et al., 2013). BALB/c mouse intranasal
infection studies also showed that in addition to AmrAB-OprA,
BpeAB-OprB, and BpeEF-OprC were not required for viru-
lence (Propst, 2011; Schweizer, 2012a). The AmrAB-OprA eﬄux
pump is also not required for eﬃcient killing of Caenorhabditis
elegans by B. pseudomallei (O’Quinn et al., 2001). The BpeAB-
OprB pump has been implicated in being involved in spermidine
homeostasis in strain KHW with exogenous spermidine and N-
acetylspermidine activating bpeA transcription (Chan and Chua,
2010).
Efflux Pumps in other Burkholderia
Species
Burkholderia mallei
In part due to ongoing in host evolution of this obligate
pathogen, B. mallei is generally more susceptible to antimicro-
bials than its progenitor B. pseudomallei. For instance, many B.
mallei strains are susceptible to aminoglycosides. In the ATCC
23344 prototype strain this susceptibility results from a 50 kb
chromosomal deletion encompassing the amrAB-oprA operon
(Nierman et al., 2004). Strains NCTC10229 and NCTC10247
are likely aminoglycoside susceptible because only remnants
of the amrAB-oprA operon are present (Winsor et al., 2008).
Genes and operons encoding other eﬄux pumps, including
BpeAB-OprB and BpeEF-OprC, are present but whether they
encode functional eﬄux systems remains remains to be estab-
lished.
Burkholderia thailandensis
One study indicated the presence of anMFS eﬄux pump, with an
associated regulatory protein of the multiple antibiotic resistance
regulator (MarR) family (Grove, 2010). However, expression of
the eﬄux pump was only responsive to urate, xanthine, and
hypoxanthine and thus the signiﬁcance of this transporter in B.
thailandensis’ antibiotic resistance, if any, is unclear.
In contrast, the contributions of RND pumps to this bac-
terium’s antibiotic resistance have been established. It was
shown that chloramphenicol exposure selects for expression
of an RND eﬄux pump, BpeEF-OprC, that also extrudes
ﬂuoroquinolones, tetracycline, and trimethoprim (Biot et al.,
2011). Doxycycline selection resulted in mutants that either
over-expressed AmrAB-OprA or BpeEF-OprC, and exhibited
the multidrug resistance proﬁles associated with expression
of these eﬄux pumps (Biot et al., 2013). Mutational anal-
ysis of these mutants suggested that BpeAB-OprB could at
least partially substitute for absence of either AmrAB-OprA or
BpeEF-OprC. Unlike other Gram-negative bacteria, cell enve-
lope properties, eﬄux pump repertoire, and resulting drug
resistance proﬁle make B. thailandensis suitable as a B. pseu-
domallei BSL-2 surrogate for drug eﬃcacy studies (Schweizer,
2012c).
Burkholderia vietnamiensis
Transposon mutagenesis studies aimed at identiﬁcation of
polymyxin B susceptible mutants identiﬁed a gene encoding a
NorM multidrug eﬄux protein (Fehlner-Gardiner and Valvano,
2002).While norM expression in an E. coli acrAB deletionmutant
complemented its norﬂoxacin susceptibility, its inactivation in B.
vietnamiensis only aﬀected susceptibility to polymyxin but not
other antibiotics.
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Unlike other Burkholderia species, including most BCCmem-
bers, the majority of environmental and clinical B. vietnamien-
sis isolates are aminoglycoside susceptible (Jassem et al., 2011).
Aminoglycoside resistance as a result of chronic infection or in
vitro exposure to aminoglycosides is the result of the AmrAB-
OprM eﬄux pump, which is most likely a homolog of B. pseu-
domallei and B. thailandensis AmrAB-OprA (Jassem et al., 2011,
2014). Of note is the observation that eﬄux pump expression
in mutants that acquired resistance during infection was due to
missense mutations in the amrAB-oprM regulator amrR, but not
those mutants derived from antibiotic pressure in vivo (Jassem
et al., 2014).
Burkholderia Efflux Pump Mutants as
Experimental Tools
The high-level intrinsic antibiotic resistance of many
Burkholderia species complicates their genetic manipulation,
use in studies of intracellular bacteria with the aminoglycoside
protection assay, and drug eﬃcacy studies. It has been shown
that eﬄux-compromised mutants of B. cenocepacia and B. pseu-
domallei greatly facilitate genetic manipulation of these species,
as well as cell invasion studies using the aminoglycoside pro-
tection assay (Dubarry et al., 2010; Hamad et al., 2010; Campos
et al., 2013). Eﬄux-compromised strains of B. thailandensis and
B. pseudomallei strains have also proved useful for study of the
eﬄux propensity of novel antimicrobial compounds (Liu et al.,
2011; Mima et al., 2011; Teng et al., 2013; Cummings et al., 2014).
Conclusion
Burkholderia species are well adapted to life in diverse, often
adversarial, environments including those containing antimicro-
bials. This adaptation is facilitated by large genomes that bestow
on the bacteria the ability to either degrade or expel noxious
chemicals. As a result, opportunistic infections by pathogenic
members of this species are diﬃcult to treat because of intrinsic
antibiotic resistance and persistence in the presence of antimi-
crobials. Resistance is in large part attributable to eﬄux pump
expression, mostly members of the RND family. While the last
decade has seen signiﬁcant progress in study of drug eﬄux in
Burkholderia species, progress still lags signiﬁcantly behind other
opportunistic pathogens, e.g., P. aeruginosa and A. baumannii,
where eﬄux pumps also play signiﬁcant roles in intrinsic and
acquired drug resistance.
There are some unique aspects of eﬄux systems in
Burkholderia species that are without parallel and studies of these
may shed light on unique physiological functions of eﬄux pumps
in these organisms. For instance, the ﬁrst gene in the bpeEF-
oprC operon, llpE, is co-transcribed with the genes encoding the
BpeEF-OprC eﬄux pump components (Nair et al., 2004, 2005).
Its deletion neither aﬀects eﬄux pump function nor speciﬁcity
for known antibiotic substrates. It is highly conserved through-
out the Burkholderia genus and found in all sequenced genomes
(Winsor et al., 2008). Based on homology, LlpE probably is an
enzyme of the alpha/beta hydrolase family, recently annotated as
a putative lipase/carboxyl esterase, and its conservation through-
out the genus suggests an adaptation or survival beneﬁt in a niche
environment. The unique association of this enzyme with BpeEF-
OprC and its role in Burkholderia biology warrant further studies
of this enzyme.
When reviewing the B. cenocepacia eﬄux pump literature it
becomes evident that eﬄux pump nomenclature in this species,
especially that of the RND family is non-uniform and con-
fusing (for instance CeoAB-OpcM, RND-1 to RND-16, BCA
gene names, Mex1, orf, etc.), which makes comparisons with
other Gram-negative bacteria unnecessarily cumbersome. As
with other Gram-negative bacteria, the nomenclature initiated in
B. cenocepacia by Dr. Jane Burns’ laboratory in the early 2000s,
i.e., CeoAB-OpcM (Nair et al., 2004), would make the most
sense and it is a pity that it was not followed in subsequent
studies.
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